Dosimetric characterization of an image-guided stereotactic small animal irradiator

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Physics in Medicine and Biology (Impact Factor: 2.76). 03/2011; 56(8):2585-99. DOI: 10.1088/0031-9155/56/8/016
Source: PubMed

ABSTRACT Small animal irradiation provides an important tool used by preclinical studies to assess and optimize new treatment strategies such as stereotactic ablative radiotherapy. Characterization of radiation beams that are clinically and geometrically scaled for the small animal model is uniquely challenging for orthovoltage energies and minute field sizes. The irradiator employs a commercial x-ray device (XRAD 320, Precision x-ray, Inc.) with a custom collimation system to produce 1-10 mm diameter beams and a 50 mm reference beam. Absolute calibrations were performed using the AAPM TG-61 methodology. Beam's half-value layer (HVL) and timer error were measured with an ionization chamber. Percent depth dose (PDD), output factors (OFs) and off-axis ratios were measured using radiochromic film, a diode and a pinpoint ionization chamber at 19.76 and 24.76 cm source-to-surface distance (SSD). PDD measurements were also compared with Monte Carlo (MC) simulations. In-air and in-water absolute calibrations for the reference 50 mm diameter collimator at 19.76 cm SSD were measured as 20.96 and 20.79 Gy min(-1), respectively, agreeing within 0.8%. The HVL at 250 kVp and 15 mAs was measured to be 0.45 mm Cu. The reference field PDD MC simulation results agree with measured data within 3.5%. PDD data demonstrate typical increased penetration with increasing field size and SSD. For collimators larger than 5 mm in diameter, OFs measured using film, an ion chamber and a diode were within 3% agreement.

Download full-text


Available from: Strahinja Stojadinovic, Sep 26, 2015
57 Reads
  • Source
    • "Relative dosimetry of very small field sizes. Several studies have determined the relative dosimetry data for kilovoltage x-rays used for intraoperatative radiation therapy (IORT) and animal irradiators often with very small field sizes (Eaton and Duck 2010, Eaton 2012, Ebert et al 2009, Newton et al 2011, Pidikiti et al 2011). The IORT x-ray units typically deliver x-rays with peak potentials of 50 kVp. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This topical review provides an up-to-date overview of the theoretical and practical aspects of therapeutic kilovoltage x-ray beam dosimetry. Kilovoltage x-ray beams have the property that the maximum dose occurs very close to the surface and thus, they are predominantly used in the treatment of skin cancers but also have applications for the treatment of other cancers. In addition, kilovoltage x-ray beams are used in intra operative units, within animal irradiators and in on-board imagers on linear accelerators and kilovoltage dosimetry is important in these applications as well. This review covers both reference and relative dosimetry of kilovoltage x-ray beams and provides recommendations for clinical measurements based on the literature to date. In particular, practical aspects for the selection of dosimeter and phantom material are reviewed to provide suitable advice for medical physicists. An overview is also presented of dosimeters other than ionization chambers which can be used for both relative and in vivo dosimetry. Finally, issues related to the treatment planning and the use of Monte Carlo codes for solving radiation transport problems in kilovoltage x-ray beams are presented.
    Physics in Medicine and Biology 02/2014; 59(6):R183-R231. DOI:10.1088/0031-9155/59/6/R183 · 2.76 Impact Factor
  • Source
    • "Radiation was carried out using an X-ray image guided small animal irradiator as previously described (7,8). The irradiator is characterized by a high dose rate, small beam size, accurate and precise target localization facilitated through image guidance, resulting in precision-high dose irradiation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to develop an aggressive locally advanced orthotopic prostate cancer model for assessing high-dose image-guided radiation therapy combined with biological agents. For this study, we used a modified human prostate cancer (PCa) cell line, PC3, in which we knocked down a tumor suppressor protein, DAB2IP (PC3‑KD). These prostate cancer cells were implanted into the prostate of nude or Copenhagen rats using either open surgical implantation or a minimally invasive procedure under ultrasound guidance. We report that: i) these DAB2IP-deficient PCa cells form a single focus of locally advanced aggressive tumors in both nude and Copenhagen rats; ii) the resulting tumors are highly aggressive and are poorly controlled after treatment with radiation alone; iii) ultrasound-guided tumor cell implantation can be used successfully for tumor development in the rat prostate; iv) precise measurement of the tumor volume and the treatment planning for radiation therapy can be obtained from ultrasound and MRI, respectively; and v) the use of a fiducial marker for enhanced radiotherapy localization in the rat orthotopic tumor. This model recapitulates radiation-resistant prostate cancers which can be used to demonstrate and quantify therapeutic response to combined modality treatments.
    International Journal of Oncology 03/2013; 42(5). DOI:10.3892/ijo.2013.1858 · 3.03 Impact Factor
  • Source
    • "The device was operated at 250 kV and 1 mA, producing a dose rate of 1.27 Gy/min. Dosimetric calibration of the device was performed according to national protocols and has been described previously [21]. The small animal irradiator is equipped with a portable gas anesthesia device. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is clinical interest in the modulation of regulatory T cells for cancer therapy. The safety of these therapies in combination with conventional anti-cancer therapies, including radiation therapy, can be studied in animal models. The effects of partial depletion of regulatory T (Treg) cells with an anti-CD25 antibody in conjunction with ionizing radiation on inflammation and tissue injury were analyzed in C57BL/6 mice. An anti-CD25 antibody (PC61) was administered 3 days prior to 13 Gy lower-half hemi-body irradiation (HBI). The blood, spleen, mesenteric lymph nodes (mLNs) and inguinal lymph nodes (iLNs) were harvested at various times thereafter. Alterations in the proportion of leukocyte subsets including CD4(+) T cells, CD8(+) T cells, Treg cells, B cells, NK cells, NK1.1(+) T cells, macrophages and granulocytes were analyzed by FACS. The lungs, liver, pancreas, stomach, jejunum, duodenum, ileum, colon and kidney were harvested and studied by H&E staining. Expression of inflammatory mediators in plasma and tissue were investigated by ELISA. HBI significantly decreased the leukocyte pool though the various leukocyte subsets had different sensitivities to HBI. The administration of PC61 significantly decreased the proportion of Treg cells in spleen, iLN, mLN and blood (reduction of approximately 60%). Irradiation significantly increased the proportion of Treg cells in the spleen, iLN and mLN. HBI induced a systemic inflammatory reaction as demonstrated by increased plasma levels of IL-6, KC/CXCL1 and circulating granulocytes in the blood. Neutrophils also infiltrated the small bowel. The same general patterns were observed whether or not Treg cells were partially depleted with PC61 prior to HBI. These data demonstrate that partial depletion of Treg cells in these mice does not influence HBI-induced inflammatory response and tissue injury, and that combining anti-CD25 therapy with radiation may be safe and well tolerated in a clinical setting.
    PLoS ONE 02/2013; 8(2):e56607. DOI:10.1371/journal.pone.0056607 · 3.23 Impact Factor
Show more